Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.41 |
| ▸ | ACACB | O00763 | 5/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149709 | 0.88 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3ACACB | |
| SCHEMBL18531937 | 0.84 | ACACB (0.38) | ACACBMTNR1AMTNR1B | |
| SCHEMBL2760163 | 0.80 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2736123 | 0.78 | ACACB (0.38) | ACACBMTNR1AMTNR1B | |
| SCHEMBL27396612 | 0.78 | TAS1R3 (0.47) | ACACBMTNR1AMTNR1B | |
| SCHEMBL13645890 | 0.78 | TAS1R3 (0.47) | ACACBMTNR1AMTNR1B | |
| SCHEMBL13780653 | 0.77 | ACACB (0.37) | ACACBMTNR1AMTNR1B | |
| SCHEMBL2736111 | 0.76 | MTNR1A (0.43) | ACACBMTNR1AMTNR1B | |
| SCHEMBL18531990 | 0.74 | MTNR1A (0.42) | ACACBMTNR1AMTNR1B | |
| SCHEMBL13242519 | 0.74 | GABRP (0.43) | ACACBMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| US-9139541-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140017199-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8486942-B2 | Modulators of pharmacokinetic properties of therapeutics | Gilead Sciencs, Inc. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120237478-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8148374-B2 | Concurrent administering of drugs; side effect reduction | GILEAD SCIENCES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8067449-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7939553-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2009008989-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008103949-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| WO-2008010921-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | PNP, UNG, PNPO | CHRNB2 4453/4885CHRNA4 4309/4885CHRNB4 4313/4885 |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3124/4885CHRNA4 3196/4885CHRNB4 2573/4885 |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3164/4885CHRNA4 3183/4885CHRNB4 2529/4885 |
| US-20140017199-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3164/4885CHRNA4 3183/4885CHRNB4 2529/4885 |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3164/4885CHRNA4 3183/4885CHRNB4 2529/4885 |
| US-20120237478-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CHRNB2 3164/4885CHRNA4 3183/4885CHRNB4 2529/4885 |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CHRNB2 3244/4885CHRNA4 4161/4885CHRNB4 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.